Insider Selling: Clearside Biomedical, Inc. (NASDAQ:CLSD) Insider Sells 8,000 Shares of Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD) insider Daniel H. White sold 8,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $9.75, for a total value of $78,000.00. Following the sale, the insider now directly owns 499,967 shares of the company’s stock, valued at approximately $4,874,678.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Clearside Biomedical, Inc. (CLSD) opened at 7.13 on Thursday. The stock’s market cap is $180.39 million. Clearside Biomedical, Inc. has a 52 week low of $5.44 and a 52 week high of $25.08. The company has a 50-day moving average price of $9.17 and a 200-day moving average price of $8.06.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, May 10th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.03. The business had revenue of $0.01 million for the quarter. Clearside Biomedical had a negative return on equity of 53.20% and a negative net margin of 154,030.02%. Equities analysts anticipate that Clearside Biomedical, Inc. will post ($1.72) EPS for the current year.

WARNING: This news story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://sportsperspectives.com/2017/08/10/daniel-h-white-sells-8000-shares-of-clearside-biomedical-inc-nasdaqclsd-stock-updated-updated.html.

CLSD has been the subject of a number of analyst reports. Cowen and Company reissued a “buy” rating on shares of Clearside Biomedical in a research note on Monday. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Monday, May 15th. ValuEngine raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. JMP Securities began coverage on Clearside Biomedical in a research note on Thursday, May 25th. They issued an “outperform” rating and a $21.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $27.00 price target on shares of Clearside Biomedical in a research note on Thursday, April 20th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $19.00.

Several hedge funds and other institutional investors have recently made changes to their positions in CLSD. A.R.T. Advisors LLC purchased a new position in shares of Clearside Biomedical during the fourth quarter worth $101,000. Wells Fargo & Company MN raised its position in shares of Clearside Biomedical by 325.0% in the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock worth $133,000 after buying an additional 12,800 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Clearside Biomedical during the second quarter worth $137,000. TIAA CREF Investment Management LLC raised its position in shares of Clearside Biomedical by 30.7% in the first quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after buying an additional 4,527 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Clearside Biomedical during the first quarter worth $178,000. 49.67% of the stock is currently owned by institutional investors and hedge funds.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply